The publication / Sources
Provider pages describe an offer. Studies describe an experiment. Neither replaces an individual clinical assessment.
Sources retain individual check dates and scope notes. Current product records, purchase policies, regulatory guidance and research answer different questions; a retrieval date is not a study publication date.
Rechecked current ingredient descriptions and strengths, $48/month starting offer, hormone and application cautions, and dedicated /go/timeout consultation CTA. Manufacturer claims and timelines are not exact-formula trial outcomes; personal total and eligibility unverified.
Checked 2026-09-27Current product and supply-price details, checked with TinyFish and a rendered browser page. Marketing claims are attributed.
Checked 2026-09-27Rendered page confirms two-month auto-refill and a separate one-time price. Outcomes described by Musely as self-reported.
Checked 2026-09-26Current supply price and rendered formula description. Exact prescribed strengths require confirmation.
Checked 2026-09-26Supply presentation and care pathway; published review-time estimate differs from the product page.
Checked 2026-09-26Current $159 three-month offer, named ingredients, and fragrance-free claim. Retrieved page’s clinical-results block names the face cream; serum concentration, full panel, and serum-specific trial report not verified.
Checked 2026-09-26Establishes separate cream, serum, eye, and body products with distinct offers. Range-wide study summaries and bundle claims are not treated as proof for every formula.
Checked 2026-09-270.2% estriol in a peptide-rich base, $195 three-month offer and 12-week n=38 study summary. Full study protocol/results and complete base not obtained; headline perceptions are not instrumental effect sizes.
Checked 2026-09-27Care pathways and starting membership presentation; not a final medicine price or confirmed insurance coverage.
Checked 2026-09-27Month-to-month, three-month and annual membership prices; optional video-visit costs and prescription fulfillment distinctions. Actual checkout and individual benefits not verified.
Checked 2026-09-27Published nonreturnability of pharmaceutical medicines and payment terms; not an individualized refund determination or legal advice.
Checked 2026-09-27Retrieval exposed question headings without policy answers. No membership refund window or unused-plan credit inferred.
Checked 2026-09-27Final /go/timeout destination: $576 twelve-month plan under the $48 monthly rate; shorter totals $330/six months, $189/three months and $75/one month. Displayed monthly figures and totals differ slightly for shorter plans. No auto-billing and non-approval refund advertised; no purchase completed.
Checked 2026-09-27Official product ingredients, displayed prices and subscription renewal, checked October 4, 2026. No patient care or fulfillment test performed.
Checked 2026-10-04Plain HTTP prices; checkout unverified.
Checked 2026-11-11Plain HTTP product data.
Checked 2026-11-11Plain HTTP product data.
Checked 2026-11-11Plain HTTP provider document; not a trial.
Checked 2026-11-11Plain HTTP enrollment terms.
Checked 2026-11-11Plain HTTP description; formulation details remain incomplete.
Checked 2026-11-11States that no estriol-containing drugs are FDA-approved. General hormone information is not a product-specific risk estimate.
Checked 2026-09-27Explains that compounded drugs are not FDA-approved and distinguishes their premarket oversight.
Checked 2026-09-27February 12, 2026 announcement concerning six specified approved products. It is not approval of estriol face creams.
Checked 2026-09-26Device authorizations have defined uses; microneedling is not approved to deliver topical drugs or other products into skin. Includes a pointer to separate RF microneedling safety information.
Checked 2026-09-26Patient record-access guidance with covered-entity scope and exceptions; not a guarantee of a particular record, fee or prescription transfer.
Checked 2026-09-27Current patient information reviewed for record retrieval and correction questions; no individual legal determination.
Checked 2026-09-27State pharmacy-board verification resources; platform familiarity does not verify a dispensing pharmacy.
Checked 2026-09-27Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Official FDA questions-and-answers page read directly; concise editorial summary retained
Checked 2026-10-21October 15, 2025 notice; checked by plain HTTP.
Checked 2026-11-11Dermatology guidance about skin changes, moisturization, sun protection and assessment. Not a recommendation for a particular estriol product.
Checked 2026-09-27Medical testing for delayed contact allergy and clinical interpretation. Not a home estriol testing protocol or proof of hormone suitability.
Checked 2026-09-26General product-tolerance information and fragrance-free versus unscented distinctions. General instructions are not converted into dosing or application advice for a prescription hormone.
Checked 2026-09-26Explains systemic and local routes and individualized decision-making. General menopause therapy guidance is not a facial-estriol risk estimate; no treatment schedule is reproduced.
Checked 2026-09-26Professional assessment, procedure-specific preparation and aftercare, and home-device concerns. No combination with a facial estriol prescription is established.
Checked 2026-09-26Acne-like breakouts, color and sensation differences across skin tones, and possible eye symptoms. Used to explain assessment needs, not to diagnose readers.
Checked 2026-09-26December2021 clinical consensus reviewed in full for purpose and treatment scope. Vaginal/urogenital guidance is not facial-estriol eligibility or a facial-product risk estimate.
Checked 2026-09-27Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Abstract reviewed. Eighteen participants, six months; preliminary findings, not a trial of the current brands.
Checked 2026-09-26Abstract reviewed. Fifty-nine participants, six months; does not establish results for every compounded formula.
Checked 2026-09-26Abstract reviewed. Seventeen women over three months; limited measurements cannot exclude all systemic exposure or long-term outcomes.
Checked 2026-09-26Public 34-page report reviewed: short, single-site controlled study. Commercial sponsor is disclosed; not a comparison of all listed brands.
Checked 2026-09-26Record only. No abstract available and full text not obtained; no detailed conclusions attributed to this review.
Checked 2026-09-26Original 2026 conference abstract P-124 and its complete table, PDF page50; text and rendered page reviewed
Checked 2026-10-21Primary full article: methods, main results, participant table, figure captions, discussion and funding reviewed on publisher site
Checked 2026-10-21Historical 2024 report; reviewed November 9.
Checked 2026-11-09Homepage shipping reference; customer service and payment details supplied for this review, without a checkout or timed support test
Checked 2026-10-12Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14Public source checked for this editorial review; no product-use or transaction test.
Checked 2026-10-14